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Aim: To evaluate management of risk factor modification among patients suffering from 
coronary heart disease and to explore patients' experiences of secondary prevention. 
Methods: After institution of a secondary prevention programme patients were offered follow 
up visits to a nurse, one year after the coronary event for evaluation of various risk factors 
associated with recurrence (I, H). Self-report of smoking cessation was validated against bio­
chemical markers for smoking, cotinine in plasma and carbon monoxide in expired air (III). 
Factors that can predict who will resume smoking after an acute coronary syndrome were 
identified (IV). An in-depth interview with a narrative approach and hermeneutical analysis 
was conducted in patients after a myocardial infarction (V). 
Results: The evaluation showed that 70% of all patients had one or more of the following risk 
indicators; s-cholesterol >6.5 mmol/1 (30%), s-triglycerides >3.0 mmol/1 (19%), fasting blood 
glucose > 6.7 mmol/1 (29%), systolic blood pressure >160 mmHg (9%), diastolic blood 
pressure >90 mmHg (8%) or smoking (36%), compared with 67% at follow up (I). No change 
in mean body weight was observed (I, II). Over time a substantial lowering of serum lipids was 
observed parallel to a three-fold increase in the use of lipid-lowering drugs. 
Out of 1320 patients, with acute coronary syndromes (IV), 434 (33%) were current smokers. 
Three months after discharge 51% of those were still smoking. Six factors were independently 
associated with smoking at follow-up: non-participation in the cardiac rehabilitation 
programme, treatment with sedatives or antidepressants at time of admission, a previously 
known cardiac event or cerebral vascular disease, smoking related pulmonary disease and high 
average cigarette consumption. Of 260 former smokers, 17 (6.5%) had bio-chemical markers 
that contradicted their self-report. 
The experiences of patients following a first myocardial infarction were described as 'impact 
of medication' and 'impact of health professionals' (V). Patients interpreted bodily symptoms 
as a consequence of being medicated rather than as a result of their heart attack. The 
medication led to feelings of being intruded upon but also to feelings of security. The 
communication with different physicians and other health professionals led to some perplexity 
about the illness and its treatment. Patients expressed a need of being reassured by the 
physician regarding their physical health status. 
Conclusions: The findings indicate difficulties in the management of risk factor modification 
in secondary prevention. Although there has been a marked improvement in serum lipids levels 
by increased use of lipid lowering drugs, there are still problems with modification of life style 
related risk factors, such as overweight and smoking. With even lower treatment targets for 
hypertension there is a potential for improvement of this risk factor as well. Self-reported 
smoking cessation and bio-chemical markers corresponded in the majority of cases. Following 
a first myocardial infarction, care of patients has to be considerated regarding the impact of the 
pharmacological treatment on patients' life. The point initiation in secondary preventive work 
must be patients' beliefs about their condition and the treatment they receive. 
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ABSTRACT 
Aim: The overall aim of this thesis was to evaluate management of risk factor modification among 
patients suffering from coronary heart disease and to explore patients' experiences of secondary 
prevention. 
Methods: After institution of a secondary prevention program patients were offered follow up visits to 
a nurse, one year after the coronary event for evaluation of various risk factors associated with 
recurrence (I, II). At the follow-up visits patients' self-report of smoking cessation was validated 
against bio-chemical markers for smoking, cotinine in plasma and carbon monoxide in expired air 
(III). Factors that can predict who will resume smoking after an acute coronary syndrome were 
identified (IV). To explore patients' experiences after a first myocardial infarction in relation to 
secondary prevention, an in-depth interview with a narrative approach and hermeneutical analysis was 
conducted (V). 
Results: At the evaluation it was found that 70% of all patients had one or more of the following risk 
indicators; s-cholesterol >6.5 mmol/1 (30%), s-triglycerides >3.0 mmol/1 (19%), fasting blood glucose > 
6.7 mmol/1 (29%), systolic blood pressure >160 mmHg (9%), diastolic blood pressure >90 mmHg (8%) 
or smoking (36%), compared with 67% at follow up one to two years later (I). Thus, the secondary 
prevention program had a limited effect on the total risk factor pattern. However, over time a substantial 
lowering of serum lipids was observed parallel to a three-fold increase in the use of lipid-lowering 
drugs. Mean body weight did not change during the evaluation periods (I, II). 
Smoking habits were recorded for 1320 patients hospitalised with a diagnosis of acute coronary 
syndrome during a period of four years (IV). Of the patients admitted, 434 (33%) reported that they 
were current smokers. Three months after discharge 51 % of these were still smoking. Six factors were 
independently associated with smoking status at follow-up: non-participation in the cardiac 
rehabilitation program, treatment with sedatives or antidepressants at time of admission, a previously 
known cardiac event or cerebral vascular disease, smoking related pulmonary disease and high average 
cigarette consumption. Presence of any of these factors was associated with a higher risk of continued 
smoking. Of former smokers who visited the nurse, a total of 260 (84%) were validated by biochemical 
markers for smoking. The validation revealed that 17 (6.5%) patients had biochemical markers that 
contradicted their self-report with raised carbon monoxide values and/or raised cotinine levels without 
alternative nicotine delivery. However, in the vast majority of the patients, self-report regarding 
smoking cessation corresponded with the biochemical marker (III). 
The experiences of patients following a first myocardial infarction was interpreted and described as 
'impact of medication' and 'impact of health professionals' (V). Patients interpreted bodily symptoms 
as a consequence of being medicated rather than as a result of their heart attack. The medication led to 
feelings of being intruded upon but also to feelings of security. The communication with different 
physicians and other health professionals led to some perplexity about the illness and its treatment. 
Patients expressed a need of being reassured by the physician regarding their physical health status. 
Conclusions: The findings from this study indicate difficulties in implementation of secondary 
prevention in patients with established coronary heart disease. Although there has been a marked 
improvement in the management of serum lipids by increased use of lipid lowering drugs, there are still 
problems with modification of other life style related risk factors, such as overweight and smoking. 
With even lower treatment targets for hypertension there is a potential for improvement of this risk 
factor as well. Following a first myocardial infarction, care of patients has to be considered regarding 
the impact of the pharmacological treatment on patients' life. The point initiation in secondary 
preventive work must be patients' beliefs about their condition and the treatment they receive. 
Keywords: Coronary heart disease, myocardial infarction, secondary prevention, risk factor 
modification, smoking cessation, validation, predictors, patients' experiences, nursing. 
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INTRODUCTION 
Coronary heart disease (CHD) is a common health problem in all western countries. The 
number of patients discharged from Swedish hospitals during 2001 with ischaemic heart 
disease was approximately 50.000, of which 27.000 were after acute myocardial infarction 
(AMI) (The National Board of Health and Welfare (2003). 
Secondary prevention 
Secondary prevention encompasses all measures taken in order to reduce or alleviate adverse 
consequences of many important health problems in human beings, for example in persons 
infected with human immunodeficiency virus, and in persons suffering from cancer (Kelly et 
al. 2002; Khuri 2003; Vainio et al. 2003). Secondary prevention of coronary heart disease 
includes identification and modification of risk factors by the introduction of lifestyle 
measures and pharmacological and interventional therapy, such as coronary artery bypass 
grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) in patients with 
established coronary heart disease (Wallentin 2002) According to European and American 
guidelines on cardiovascular disease prevention, patients with clinically manifest coronary 
heart disease or other major atherosclerotic diseases, should be given the highest priority 
regarding intensive life style intervention and, when necessary, drug therapies in order to 
achieve risk factor goals, as these patients are at high risk for a further major coronary event 
(Wood 1998; Smith et al. 2001 ; De Backer et al. 2003). The strategies in secondary 
preventive work includes supporting patients in making lifestyle changes, modification of risk 
factors and medication (De Backer et al. 2003), thereby reduce the risk for premature death, 
further major cardiac events, reduce premature disability and to slow down the progression of 
the disease. The interest of secondary prevention of coronary heart disease has constantly 
increased during the last decade. When searching in Medline in the beginning of 2004 with 
the abbreviation for the various designations of the disease, i.e "IHD, CAD, CHD or MI" and 
"secondary prevention", the number of articles in this field had increased from 390 hits when 
the search was limited to the 1980s, to 2495 hits from 1990 to 2004. This indicates a great 
interest in this field, probably as a result of several studies showing significant benefits, not 
only for the individual but also for society (McMurray 1999; Unal et al. 2004). 
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Secondary prevention program at the clinic of Cardiology at Sahlgrenska University 
Hospital 
During the year 1993 prior to the evaluation in Paper I, a secondary preventive program was 
introduced in the Division of Cardiology at Sahlgrenska University Hospital. The program 
was an attempt to improve treatment of traditional risk factors (i.e smoking, hyperlipidemia, 
high blood pressure and diabetes) in patients with coronary heart disease. Guidelines were 
given as to when treatment for hyperlipidemia, hypertension and diabetes should be instituted 
as well as target goals. The author of this dissertation was the nurse designated to work with 
secondary prevention in the out-patient clinic. The aim was to improve patients' risk factor 
profile by information, education and counselling regarding lifestyle changes. Nursing 
intervention also included assisting the patients in setting risk reduction goals. Moreover, 
together with the patient, make a plan for meeting these goals and also help to identify 
barriers; such as potential misconceptions and giving support to the patients when they try to 
make life style changes. When the secondary program started at the beginning of 1993, 
guidelines on how to define the various risk factors, treatment goals for the various risk 
factors and when to institute medical treatment were set up. New guidelines were adopted by 
the clinic in 1995 based on the findings from randomised trials showing beneficial effects of 
lipid lowering therapy (The Simvastatin Survival Study Group (4S), 1994}. The 
recommendations stated in our guidelines during 1993 and 1995 are outlined in Table 1. 
Table 1. Guidelines regarding various risk indicators and treatment targets 
Risk indicators Elevated Treatment targets 
levels* 1993 1995 
Hyperlipidemia: 
Cholesterol (mmol/1) >6.5 <5.5 <5.0 
Triglycerides (mmol/1) >3.0 <3.0 <2.0 
LDL (mmol/1) >4.5 <4.0 <3.0 
Hypertension: 
Systolic blood pressure (mmHg) >160 <160 <160 
Diastolic blood pressure (mmHg) >90 <90 <90 
Diabetes: 
Fasting blood glucose (mmol/1) >6.7 <6.7 <6.7 
* Definition of elevated levels in Paper I and II 
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BACKGROUND 
Etiology and risk factors 
The dominating cause of the disease is atherosclerosis (Wallentin 2002). Development of 
atherosclerosis is regarded as being related to a lifestyle of unhealthy food, physical inactivity 
and smoking. This type of lifestyle leads, in many individuals, to adverse changes in 
biochemical and physiological characteristics that enhance the development of atherosclerosis 
and its associated complications, angina pectoris and myocardial infarction (Second Joint 
Task Force Report, 1998). Risk factors could be characterised as non-modifiable and 
modifiable. The non-modifiables are; age, sex, and personal and family history of coronary 
heart disease. The major modifiable risk factors are; hypercholesterolemia, hypertension and 
cigarette smoking. Other modifiable determinants are diabetes, obesity and physical inactivity 
(Assmann et al. 1999). With respect to the modifiable risk factors there is an agreement in the 
literature that causal and preventive risk factors are cigarette smoking, elevated cholesterol, 
hypertension, obesity, physical inactivity and diabetes as clarified by Hennekens (Hennekens 
1998). 
Manifestations of coronary heart disease 
The various manifestations of coronary heart disease are angina pectoris, i.e. chest-pain 
following exercise or eating, myocardial infarction, cardiac arrest and silent myocardial 
ischaemia, i.e. objective signs of myocardial ischaemia that can be demonstrated without 
simultaneous subjective physical symptoms. Angina pectoris is often the first symptom of the 
disease. The onset of a myocardial infarction is often sudden and without previous warning 
symptoms, and is, in many individuals, the first sign of the disease. Coronary heart disease is 
a common cause of cardiac arrest, which can also be the first sign of the disease. 
Prognosis 
Coronary heart disease is a common cause of premature death and the main cause of death in 
both men and women in all industrialised countries (Nissinen et al. 2001). In Sweden, it is the 
most common cause of death among middle-aged and older men as well as among older 
women, and the second most common cause of death among middle-aged women (The 
National Board of Health and Welfare, 2001). Thus, the long-term mortality in patients with 
established coronary heart disease has been reported to vary from 20% to 55% in 4.5 to 10 
years (Kavanagh et al. 2002; Mauri et al. 2002; Tyden et al. 2002; Spencer et al. 2003). Silent 
myocardial ischaemia is also associated with a greater risk of morbidity and mortality. In the 
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prospective population study 'Men born in 1914', men with silent ischaemia without a history 
of ischaemic heart disease had approximately 4 times a greater relative risk of fatal and non­
fatal myocardial infarction compared to men without these signs. The risk was 16 times 
greater if they also had a history of coronary heart disease (Hedblad et al. 1989). A greater 
number of patients will undergo revascularization procedures in the years following 
hospitalisation for an acute myocardial infarction (Abboud et al. 2002), or suffer from 
recurrent coronary events (Stevenson et al. 1994). Similarly, among patients having 
undergone mechanical revascularisation, the rate of recurrence is not insignificant (Bradshaw 
et al. 2002). 
The concept of risk 
Researchers from various disciplines have been aware of the concept of risk (Beck et al. 1992; 
D'Agostino et al. 2000; Momtahan et al. 2004). There seems to be a common notion of modern 
'Western' society as a risk culture, where many of the risks and hazards of society is a product 
of civilization itself (Beck et al. 1992). There is a great deal of evidence that the standard of 
living in a modern culture with physical inactivity, a diet rich in saturated fats and calories and 
tobacco smoking, has played an important role as the contributing factor in the risk of coronary 
artery disease, and as a cause for the high occurrence of the disease in the population (Yusuf et 
al. 2001). 
Risk is, however, a concept with various meanings. Dictionary definitions of risk include: 
possible harm, chance or possibility of danger. Synonyms are: danger, jeopardy, peril, hazard, 
menace and threat. Antonyms for risk are conceivability, possibility (Oxford English 
Dictionary and Thesaurus, 2004). The original meaning of 'risk', as discussed by Adelswärd 
(Adelswärd et al. 1996), is neutral, referring to probability, or the mathematical likelihood of 
an event occurring. In this usage of the term, the risk of an event occurring could be related to 
either a negative or a positive outcome (Altman 1991). Accordingly, risks have, to some 
degree, to do with something that could be expected, with a future component. However, the 
word "risk" has changed its meaning in today's society and has been associated with danger, a 
danger that has not yet happened but is threatening (Beck 1992). In this way, the meaning of 
risk as danger is used within the health care system and consequently 'high risk" has now taken 
on the meaning of a lot of danger' (Douglas 1992). 
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Medical science has provided society with information regarding various risks connected with 
the likelihood of suffering a disease, and also calculates how these risks could be decreased. 
There is an agreement in the medical literature that patients with established coronary heart 
disease are regarded as 'high risk' patients (Smith et al. 2001; De Backer et al. 2003) i.e. they 
have a high risk of recurrence. 
Nursing science is, in many spheres, involved in the risk-concept of the population, such as 
assessing health risk status, identifying various risk behaviours and development of 
educational strategies to reduce the risk for diverse health problems (Chyun et al. 2003; Miller 
et al. 2003; Niederhauser et al. 2004; Whitehead et al. 2004). 
Risk indicators associated with development and recurrence of coronary 
heart disease 
Hypercholesterolemia 
High serum cholesterol, i.e. high levels of total serum cholesterol and low-density lipoprotein 
cholesterol (LDL), is one of the major risk factors for development of coronary heart disease. 
There is a strong positive association between plasma serum cholesterol and risk for coronary 
heart disease events (Neaton et al. 1992; Smith et al. 1992). This association applies to 
healthy individuals, to patients with established coronary heart disease and to women as well 
as men, as clarified in the Second Joint Task Force Report of European and other societies on 
coronary prevention (1998). In addition, several clinical trials demonstrate the benefits of 
lipid lowering therapy in reducing the risk for coronary heart disease in healthy individuals 
and in persons with established disease. In primary prevention studies, a significant reduction 
of relative risk for major coronary events was demonstrated with cholesterol reduction 
therapy (Shepherd 1995; Downs et al. 1998). In secondary prevention trials, treatment with 
lipid lowering therapy reduced the risk of new coronary heart disease events by up to 42% 
(The 4S-study Group, 1994; Sacks et al. 1996; LIPID Study Group, 1998; Heart Protection 
Study Collaborative Group, 2002; Cannon et al. 2004), and a reduction of the risk of dying by 
30% (The 4S-Study Group, 1994). There are also indications that intensive lipid lowering is 
better than moderate lipid lowering (Cannon et al. 2004; Nissen et al. 2004). 
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Hypertension 
Hypertension is one of the major risk factors for coronary heart disease and stroke (Kannel, 
2000a; Kannel, 2000b; Psaty, 2001), and the risk of stroke after myocardial infarction is not 
negligible, with approximately 1 in 40 of elderly patients suffering stroke within 6 months 
subsequent to discharge following myocardial infarction (Lichtman et al. 2002). In primary 
prevention, data from the Framingham study supports the benefits of treatment of 
hypertensive patients, with a 60% reduction in absolute risk of cardiovascular mortality 
(Sytkowski et al. 1996). There is, nevertheless, limited information about blood pressure 
control and outcomes after coronary events. However, following myocardial infarction, 
angina pectoris or PTCA, blood pressure elevation has been associated with an increased risk 
of reinfarction and death (Flack et al. 1995; Amar et al. 2002; Tsang et al. 2002). As far as we 
know, there are no secondary prevention trials evaluating blood pressure reduction after 
myocardial infarction or coronary intervention, however, several studies with antihypertensive 
drugs have shown secondary preventive effects when given to patients following myocardial 
infarction (Hjalmarson et al. 1981; Dargie 2001) and after various manifestations of 
atherosclerotic disease (Yusuf et al. 2000). Drugs used were betablockers (Hjalmarson et al. 
1981; Dargie 2001) and ACE inhibitors (Yusuf et al. 2000). However, the reduction ofblood 
pressure was moderate and the association between blood pressure reduction and effect was 
not clear. Data from Women's Antioxidant Cardiovascular Study, an ongoing randomised 
secondary prevention trial of antioxidant vitamins, folic acid and vitamins B6 and B12 in 
5218 women with cardiovascular disease or three or more risk factors, showed a strong 
relationship between increasing systolic blood pressure and the risk of secondary 
cardiovascular events (Mason et al. 2004). 
Smoking 
Smoking is one of the major risk factors for the development of cardiovascular disease (Doll 
et al. 1994; Prescott et al. 1998), and associated with an adverse prognosis once the disease is 
established (Wilhelmsen 1988; Parish et al. 1995). There is, to our knowledge, no randomised 
study showing the effect of smoking cessation on health following a coronary event. To set up 
such a study would require that one group of patients would not be allowed to stop smoking. 
It is unlikely that the Ethics Committee would ever approve such a study, by reason of the 
already well-known associations between smoking cessation and the outcome following a 
cardiac event, and the very strong association between smoking and cardiovascular disease. 
Consequently, the evidence on the effects of smoking cessation after a cardiac event is based 
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on observational studies only. Thus, several observational studies have shown that patients 
who quit smoking following myocardial infarction have a marked improvement in prognosis 
compared with those who continue (Daly, 1983; Wilhelmsen, 1988; Wilhelmsson, 1975; 
Åberg, 1983). Similar observations were made on patients who have undergone CABG (van 
Domburg et al. 2000) and PTCA (Ashby et al. 2002). It was also observed that following 
CABG, re-infarction as well as new infarctions and angina pectoris were less common among 
patients who stopped smoking than they were among those who continued to smoke as was 
concluded in a review analysis conducted by Wilhelmsen (Wilhelmsen 1998). 
In a meta-analysis by Wilson and colleagues, the odds ratio of death for smokers who stopped 
smoking after an MI was 0.54, i.e a reduction in mortality by 46% (Wilson et al. 2000). In 
another meta-analysis of observational studies that included patients diagnosed with coronary 
heart disease (previous myocardial infarction or stable or unstable angina pectoris), conducted 
by the Cochrane Library, a 36% reduction in relative risk of all cause mortality was found in 
patients who quit compared with those who continued smoking (Critchley et al. 2003). Thus, 
as clarified by Richard Edwards, smoking cessation may be even more protective than 
conventional standard treatments for myocardial infarction, including thrombolysis, aspirin, 
beta-blockers and statins (Edwards 2004). 
Diabetes 
Diabetes is associated with a marked increase in the risk of coronary heart (Kannel et al. 
1979; Stamler et al. 1993). There are also indications of an elevated risk of cardiovascular 
disease even before the clinical diagnosis of diabetes (Coutinho et al. 1999). Diabetes is also 
an unfavourable prognostic factor following myocardial infarction (Zuanetti et al. 1993), 
invasive therapy of unstable coronary heart disease (Norhammar et al. 2004), CABG (Herlitz 
et al 1996) or PTCA (Mathew et al. 2004). Furthermore, diabetic patients without previous 
myocardial infarction have as high a risk of myocardial infarction as non-diabetic patients 
with previous myocardial infarction (Haffner et al. 1998). 
Sedentary lifestyle factors and effects ofphysical training 
The hazards of being physically inactive are clearly demonstrated (US department of Health 
and Human Services, 1996) and a sedentary lifestyle is considered one of the five major risk 
factors for development of cardiovascular disease (Myers 2003). In healthy people, regular 
physical activity is linked to a significant reduction in this risk (Pate et al. 1995). In a 
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coronary population, there is consistent evidence of the benefits of exercise training as 
reviewed by the Agency for Health Care Policy and Research (Wenger 1995). According to 
that review, exercise training decreases both angina pectoris in patients with coronary heart 
disease and symptoms of heart failure in patients with left ventricular systolic dysfunction. In 
a meta analysis conducted by the Cochrane Library (Jolliffe et al. 2003), exercise-based 
interventions reduced cardiac mortality by 31% in patients with coronary heart disease. There 
was no evidence of an effect of the interventions on the occurrence of non-fatal myocardial 
infarction (Jolliffe et al. 2003). 
Psychosocial factors 
The evidence for linking psychosocial factors to development of coronary heart disease is 
composed of data largely related to specific psychosocial domains such as depression, 
anxiety, personality factors and character traits, social isolation and chronic life stress 
(Rozanski et al. 1999). These factors can significantly contribute to development of coronary 
artery disease as pointed out in the review by Rozanski (1999). In another review of 
prospective cohort studies by Alboni (2003), a low socioeconomic status was associated with 
more advanced disease as shown by a significantly higher prevalence of heart failure and of 
recurrent coronary events in patients hospitalised for acute coronary infarction. The mortality 
was significantly higher in the most deprived group (Alboni et al. 2003). Further, in a 
systematic review of prospective studies Hemingway and co-workers (1999) concluded that 
there is evidence for an association between depression, social support, and psychosocial 
work characteristics among patients with cardiovascular heart disease, etiology and prognosis, 
but there are, however, conflicting data from randomised studies whether psychosocial 
interventions reduce mortality after myocardial infarction (Hemingway et al. 1999). 
Dietary factors 
Epidemiological (Kromhout et al. 1995; Joshipura et al. 2001) studies have shown that diet 
has a correlation with development of coronary heart disease and that the risks associated with 
a high fat diet remains even after the disease is established (Wong et al. 1989). It is difficult 
to conduct controlled dietary intervention studies because of the difficulties of controlling 
peoples' food choices. Results of dietary interventions in secondary prevention have not been 
conclusive. In the Diet and Reinfarction Trial (DART) (Burr et al. 1989) for example, no 
effect was demonstrated on re-infarction or death from coronary heart disease in men 
16 
recovering from a myocardial infarction. However, an independent dietary effect was 
indicated in the patients advised to eat fatty fish on all-cause mortality, which was 29% lower 
at 2 years compared to a control group. However, in a 10-year follow-up of participants in the 
DART study no substantial survival benefits were observed (Ness et al. 2002). A lack of 
benefits of dietary advice was also shown in a study on men with angina pectoris (Burr et al. 
2003). 
However, in a study (Singh et al. 1992) on patients in coronary care units with the diagnoses 
of definite or possible myocardial infarction and unstable angina pectoris, patients were 
randomised to add fruit, vegetables, nuts and fish to a fat reduced diet. The incidence of new 
cardiac events was significantly reduced in the intervention group compared to a fat reduced 
diet only and cardiac mortality was reduced by 42%. 
In the Lyon Diet Heart Study, patients were followed after their first myocardial infarction (de 
Lorgeril et al. 1999), the intervention group was recommended a Mediterranean type of diet 
comprising more bread, more root vegetables and green vegetables, bird meat, more fish, 
rapeseed oil, fruit and vegetables and less meat, butter and cream. After four years, the rate of 
cardiac death and non-fatal reinfarction in the experimental group was significantly lower 
than in the control group, which was recommended a diet usually prescribed after myocardial 
infarction. Similar benefits after dietary intervention have been demonstrated in studies that 
also included healthy subjects at high risk for coronary heart disease (Singh et al. 2002). 
Other factors associated with outcome 
There are several other factors associated with a clinical outcome e.g. the size of the heart 
muscle damage, remaining myocardial ischaemia and severe arrhythmias that are probably 
linked to recurrence, this is not however, encompassed in this thesis. 
RATIONALE FOR THE STUDY 
This study was conducted in light of convincingly scientific evidence of the benefits of risk 
factor modification in people with coronary heart disease. In addition, coronary heart disease 
is also a widespread health problem in the entire Western world (Yusuf et al. 2001). 
Furthermore, the care for patients with this diagnosis has changed towards shorter hospital 
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stays in Sweden (Stenestrand 2002) as in other countries (Spencer et al. 2004), which is why 
risk factor modification often becomes a task for the out-patient care. Against this 
background, it seemed important to evaluate the management of risk factors in patients who 
had been hospitalised with coronary heart disease and also to what extent these factors could 
be reduced. To obtain this knowledge it was necessary to have an outside perspective; i.e 
examine the medical records to find patient' characteristics and use measurements to define 
the various risk factors. 
However, modification of risk factors involves not only medical evaluation and prescription 
of medicine by the physicians, counselling and providing information by the nurses. It also 
involves patients and their view of the different treatments and their response to this 
treatment, which is why it is also important to learn about patients' experiences'. To learn 
about risk factor modification from this perspective it was important to apply an inside 
perspective, namely attempting to learn how the patients experience secondary prevention. 
Information regarding this perspective makes it possible to adapt the information and 
counselling to the patient's point of view. 
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AIMS OF THE STUDY 
The overall purpose of this thesis was to evaluate management of risk factor modification in 
patients with coronary heart disease and to explore patients' experiences of secondary 
prevention. 
The specific aims of the study were: 
- To describe the occurrence of traditional risk indicators associated with recurrence of an 
ischaemic event among patients with various manifestations of coronary heart disease, and 
to evaluate the impact of the implementation of a secondary preventive program on such 
risk indicators (I) 
- T o  e v a l u a t e  t o  w h a t  e x t e n t  i n c r e a s e d  k n o w l e d g e  o f  t h e  b e n e f i c i a l  v a l u e s  o f  l i p i d  l o w e r i n g  
treatment influenced lipid levels and the use of lipid lowering drugs after a coronary event (II) 
- To establish the reliability of self-report about smoking cessation amongst patients with 
coronary heart disease (III) 
- T o  i d e n t i f y  f a c t o r s  t h a t  c a n  p r e d i c t  w h o  w i l l  r e s u m e  s m o k i n g  a f t e r  h o s p i t a l i s a t i o n  f o r  a n  
acute coronary syndrome (IV) 
- To explore patients' experience of secondary prevention after a first AMI (V) 
METHODS 
Methodological considerations 
In the present study, both quantitative and qualitative research methods are used. The 
questions that guided this study were; what is the occurrence of traditional risk indicators in 
patients with established coronary heart disease and how health professionals succeed in 
managing the modification of these risk factors. Quantitative research methods are useful 
when the researcher wants to describe variables, examine relationships and determine 
causality among variables (Burns et al. 1997). Traditionally researchers in this area raise 
questions about different characteristics that are measurable in some way, and assign these 
characteristics a numerical value (Hartman 1998). A quantitative approach seemed therefore 
appropriate in directing the study. Qualitative research methods are useful when the 
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researchers wish to explore meanings of social phenomena as experienced by individuals 
themselves. As it was not possible to gain knowledge of patients' experiences with 
quantitative methods, it was necessary to complement with a qualitative method. 
Although quantitative and qualitative methods are derived from different traditions of 
thoughts, in theoretical science (Hartman 1998) quantitative and qualitative research methods 
may be seen as complementary (Malterud 2001) as they generate different kinds of 
knowledge that are useful in clinical practice (Burns, 1997; Boyd, 1993). According to Boyd 
(1993) it is possible to combine these methods when the purpose is "to achieve a more 
comprehensive understanding of a phenomenon that has multiple perspectives to consider". In 
this study the qualitative method was used to achieve a more complete understanding of the 
two perspectives described above. Application of qualitative methods in medical research can 
also broaden the understanding of clinical realities (Malterud 2001). 
Participants 
All the participating patients were followed up after hospitalisation at the outpatient clinic at 
the Division of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden. 
All patients living in the catchment area of Sahlgrenska Hospital in the municipality of 
Göteborg who were under the age of 70 years and had either developed acute myocardial 
infarction or had undergone PTCA or CABG between ls< January and 31st December 1993 
and discharged from the hospital, were evaluated regarding various risk indicators at event 
and one year later (Paper I). Those who had had an event between 1st September 1995 and 
31st August 1996 (Paper II) were evaluated one year thereafter. In Paper III, 556 consecutive 
patients under the age of 75 years, who visited the nurses (from 6th January 1997 to 5th 
February 1998) at the outpatient clinic for a routine follow-up 3 or 12 months after 
hospitalisation for a coronary heart event, were included in the study. Of these, 308 reported 
that they were former smokers and thereby formed the study population. Paper IV dealt with 
348 current smokers below the age of 75 years, admitted to the coronary care unit of 
Sahlgrenska University Hospital, with a diagnosis of acute coronary syndrome, between 
September 1995 and September 1999. 
In Paper V, consecutive patients with a first myocardial infarction, who visited the cardiac 
preventive nurse at the outpatient clinic during March to September 2002, were asked to 
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participate in the interview. The nurse asked patients that had no communication problem, if 
they were willing to narrate their experiences. Since the purpose was to explore patients' 
experiences after a first myocardial infarction in relation to secondary prevention, we 
therefore included all relevant patients. 
A sample of 20 patients (12 men and 8 women) were selected and interviewed. Another four 
patients were selected but they were unwilling to participate because of emotional reasons or 
lack of time. None of the patients was previously treated for coronary heart disease except for 
one that had a history of angina pectoris. Patients that had undergone CABG during 
hospitalisation were not considered. 
Table 1. A summary of the participating patients in the studies 
Patients n Paper 
Patients under the age of 70 years with 
AMI, CABG and PTCA 
293 
284 
I 
II 
Patients under the age of 75 years with 
AMI, CABG and PTCA 
308 III 
Patients under the age of 75 years with 
acute coronary syndromes 
348 IV 
Patients between 34 and 79 years with 
a first time AMI 
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Methods in the quantitative studies 
Data collection and procedure 
To gain a systematic understanding of the occurrence of risk factors, a data questionnaire was 
developed in the evaluation studies (Paper I and II). This tool was designed to obtain 
information on any previous history of diabetes, hypertension, and hyperlipidemia, as well as 
serum lipid levels, blood glucose values, smoking habits and blood pressure values. Data 
regarding previous history was based on interviews in combination with audit of the medical 
records. Patients were screened on two occasions regarding their risk factors. The first 
screening was made at onset of the event and the second screening at a mean time of 450 days 
later. This second screening is also referred to as period 1 in Paper II. In the second 
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evaluation study (Paper II), patients were approached by the outpatient clinic 1 year after the 
event for collection of the data. Data from this screening is referred to as period II. 
Blood samples were drawn for measurements of blood glucose and serum lipids including 
serum cholesterol, triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL). All determinations of serum lipids and blood glucose were made in a fasting state. 
Smoking habits were based on patients' self-reports (Paper I, II, IV). Self-reports were 
validated with biochemical markers in Paper III. 
By using a structured questionnaire the nurse at the out-patient clinic interviewed the patients 
regarding out their smoking habits (Paper III). Based on the answers in this interview they 
were classified as smokers, former smokers or non-smokers. Former smokers were asked to 
complete the self-report with samples of blood for measurements of cotinine levels and 
carbon monoxide in expired air for validation. 
Validation of smoking status 
Plasma cotinine 
Cotinine is the major metabolite of nicotine with a half-life in the blood of about 20 hours. 
The presence of nicotine, through its metabolite cotinine, was measured by capillary gas 
chromatography after a single-step liquid-liquid extraction of the plasma samples. Cotinine 
was detected by means of a nitrogen-sensitive detector giving high selectivity and sensitivity. 
In an earlier validation of the method, the limit of quantification had been set to 3.8 ng mL"' 
(Olsson P et al. 1991). The accuracy and precision of the method and instrumentation was 
checked by means of quality control samples, which were analysed together with the study 
samples. 
Carbon monoxide (CO) in expired air 
CO is present in tobacco smoke and has a half-life in the body of about 4 hours. The 
concentration in expired air was measured using a portable CO analyser (Bedfont EC50 
Carbon Monoxide Monitor). The monitor was standardized and calibrated against a control 
gas as recommended by the manufacturer. CO-values equal to or greater than 10 p.p.m. were 
considered to be an indicator of active smoking. 
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Blood pressure measurement 
Data regarding blood pressure were drawn from measurements at the clinic. Blood pressure 
was measured in supine position after 5 minutes rest, mostly one measurement, however, if 
values deviated from previous observation, a mean from two or three measurements was used. 
Identifying predictive factors concerning continuation of smoking 
Data were collected from the hospital medical records and included information on previous 
clinical history and various health complications during hospitalisation (Paper IV). During 
hospitalisation, a research nurse interviewed the patients by using a structured questionnaire 
in order to obtain additional information. The patients were asked to fill in the questionnaire 
about motivation to quit and health risks during hospitalisation. The nurse at the outpatient 
heart clinic then followed patients for 3 months after discharge. Those who continued to 
smoke (non quitters) were compared with those who had stopped smoking (quitters) with 
regard to age, sex, medical history, clinical course and intention to stop smoking. 
Questionnaire 
The questionnaire (Paper IV) contained five items concerning motivation to quit smoking 
and health-evaluated beliefs about smoking. (For more details see Paper IV, Table 4). The 
idea behind the questionnaire was to change behaviour, such as to quit smoking - an 
individual often does this gradually, from contemplation to action. The first two questions, 
adapted from the stage of change theory (Prochaska et al. 1983), intended to mirror their 
motivation or readiness to quit smoking, i.e. their stage of change. This theory suggests that 
behavioural change is a process that unfolds over time through a series of stages starting with 
contemplation, through preparation and culmination into action. In the contemplation stage, a 
smoker may have a slight intention to change behaviour and quit smoking, while in the 
preparation and action stages he/she already has taken some steps towards such a change or 
have quit smoking. A final step is maintenance where the individual makes an effort to 
maintain the new habit. The other three questions related to health-evaluated beliefs about 
smoking and its effect on health in general and on the heart in particular. 
Statistics 
A linear non-parametric permutation test for paired observations (one sample case) was used 
to determine differences between various measurements (Bradley 1968) in Paper I. In Paper 
II, Pitman's non-parametric test for difference between groups was used. In the evaluation of 
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proportions, Fisher's exact test was used, which is a special form of Pitman's test when the 
variables are dichotomous. To compare non-smokers, former smokers and current smokers in 
Paper III, Kruskal-Wallis test and Fisher's exact test were used, and for two-group 
comparisons Mann-Whitney U test and Fisher's exact test were used. In Paper IV, for 
differences between groups, Fisher's exact test was used for proportions and the Mann-
Whitney U test for continuous/ordered variables. To identify factors independently related to 
continued smoking, a logistic regression in a stepwise mode was performed. All p-values 
were two tailed and considered significant if less than 0.05. No correction for multiple 
comparisons has been made. P-values of borderline significance should therefore be treated 
with caution. In Paper V, only demographic and clinical factors are reported for the 
interviewed participants. A summary of the statistical analyses is outlined in Table 2. 
Table 2. Statistical analyses used in Papers I-IV in the thesis 
Paper I Paper II Paper III Paper IV 
Comoarison between erouos 
Proportions 
Fisher's exact test 
Linear non-parametric permutation test X 
X X X 
Continuous ordered variables 
Mann Whitney U test 
Kruskal-Wallis test 
Pitman's non-parametric test X 
X 
X X 
Multivariate Analvsis 
Stepwise logistic regression X 
Method in the qualitative study 
Data collection 
An in-depth face-to-face interview with a narrative approach (Mishler 1986) (V) was 
conducted. The following is an account of the procedure used to collect data for the study. 
The nurse at the outpatient clinic informed the patients, orally and in writing, about the aim of 
the study and how the interview would be conducted. The patients were then asked if they 
agreed to allow the nurse give his or her name and telephone number to the interviewer. 
24 
When permission was granted the interviewer contacted the patients about a week later, 
asking if they agreed to participate in the interview study. The interviewer also explained that 
the purpose of the study was to obtain knowledge and understanding regarding secondary 
prevention from the patients' perspective after discharge from hospital. During the telephone 
call, details about the study were explained and also how the interview would be conducted. 
After giving informed consent, time and place for the interview was set up, according to the 
patients' wishes. At the time of the interview, a written informed consent was obtained. The 
author of this dissertation conducted all the interviews. Everything was tape-recorded and 
before the recorder was switched on, it was emphasised to the patient that at any moment they 
could discontinue their participation. The patients' were also assured of confidentiality. Each 
patient was interviewed once. The interviews were performed between 4-24 weeks (median 
7 weeks) after the infarction and each interview lasted between 30 and 80 minutes (median 50 
minutes). 
The interviews 
The patients were encouraged to speak freely about their heart attack and how the period after 
discharge was experienced. No specific questions were asked. In order to reveal what is 
unknown, the focus was on the patients' narratives. The opening question was: "Could you 
please tell me what you think about when you reflect upon your heart attack." The narrative 
was then followed and only clarifying questions such as "Can you give me a specific 
example" were asked where it was thought necessary. An interview conducted in this way is 
created as a conversation between the interviewee and the interviewer (Mishler 1986; van 
Manen 1990). 
Analysis of the interviews 
All interviews were transcribed verbatim. An hermeneutic approach was used to analyse the 
interviews i.e the text that contained patients' experiences was interpreted in an attempt to 
grasp the meaning of these experiences (van Manen 1990). The interpretation is seen as a 
process that has three phases; naive reading where the whole interview text was read many 
times for a global understanding, structural analysis, where the whole text is examined and 
divided into meaning units, i.e. parts of sentences, one sentence or several sentences that are 
related through their content in order to explain what it is saying. The third phase is a 
comprehensive understanding of what the text is about. The text from all the interviews is 
seen as a whole and the understanding is developed from, and supported by, the other phases 
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(Benner 1994). This method has been used to illuminate the meaning of living with heart 
failure as narrated by elderly people (Ekman et al. 2000), and to illuminate womens' and their 
partners' experiences in connection with myocardial infarction (Svedlund et al. 2004). 
ETHICAL CONSIDERATIONS 
The local Ethics Committee at Göteborg University approved the studies presented in Papers 
III, IV and V. In the study presented in Paper III, there was a dilemma as to if it was 
ethically correct to check the validity of the patients' statement about their ex-smoking status. 
The local Ethics Committee approved the study on condition that the patients were informed 
of the test in advance. Information about the study was included in the letter informing the 
patients of the appointed time. The ethical demand of informing the patients was thereby met. 
The study presented in Paper IV was part of a prospective risk stratification study of patients 
with coronary syndromes, with patients giving their informed consent before participating in 
the main study. The studies presented in Papers I and II were initiated and performed as a 
quality assurance of secondary prevention at the out-patient clinic of cardiology and as such, 
approval was not applied for. 
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RESULTS 
Evaluation of risk factor modification management (Paper I and II) 
Occurrence of various risk indicators 
The proportion of the various risk indicators in patients at first screening is shown in Fig. 1 and 2. 
Fig 1 Proportion of patients with 
various risk indicators 
>6.5 > 5.5 > 5.2 
Total cholesterol 
mmol/l 
>4.5 > 4.0 > 3.5 >3.0 
LDL mmol/l Triglycerides 
mmol/l 
First screening 
Fi§ 2 Proportion of patients with 
various risk indicators 
Systolic blood Diastolic blood Fasting blood Smoking 
pressure pressure glucose £ 1 cig/d 
>160 mmHg >90 mmHg >6.7 mmol/l 
First screening 
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The results at the second screening appeared to be very similar to findings at the first event, with 
the exception that the proportion of smokers was significantly lower at the second screening. In all, 
70% of all patients had one or more of the following risk indicators at first screening: serum total 
cholesterol > 6.5 mmol/1, LDL-cholesterol > 4.5 mmol/l, serum triglycerides > 3.0 mmol/1, fasting 
blood glucose > 6.7 mmol/1, Systolic blood pressure > 160 mm/Hg, Diastolic blood pressure > 90 
mm/Hg or smoking as compared with 67% one to two years after the initial event (Paper I). 
Evaluation of changes in serum lipid levels and other risk factors 
Cholesterol: The mean total serum cholesterol levels fell significantly from 6.2 mmol/1 at the 
second screening in period I to 5.3 mmol/1 at the screening during period II (Paper II). The mean 
values for LDL-cholesterol were quite similar, just below 4.0 mmol at the two first screenings but 
had significantly decreased to 3.2 mmol/1 at the evaluation in period II (Paper II). 
The proportion of patients with lipid values below certain levels during the two evaluation periods 
is shown in Figure 3. The proportion of patients with total serum cholesterol of < 5.0 mmol/1 
increased significantly from 15 % at second screening in period I to 40 % at the evaluation in 
period II and for LDL-cholesterol < 3.5 mmol/1 there was a significant increase from 32% during 
period I to 68% during period II (Paper II). 
Triglycerides: The mean serum triglycerides decreased from 2.4 mmol/1 to 1.9 mmol/1 from the 
second screening in period I to the evaluation in period II. The proportion of patients with 
triglycerides <3.0 mmol/1 increased from 80% during period I to 87% during period II (Figure 3). 
Weight: Body mass index (BMI) remained similar at first and second screenings (Paper I). The 
mean body weight did not change during the two periods; it was 80.2 kg and 81.2 kg respectively 
(Paper II). 
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Fig 3 Proportion of patients with lipid values below 
certain levels 
p<0.001 p<0.001 p<0.001 p<0.001 p=0.024 
Ü Period I 
•  Period II 
<6.5 <5.0 <4.5 <3.5 <3.0 
Total cholesterol LDL mmol/l Triglycerides 
mmol/l mmol/l 
Smoking: Among patients with acute myocardial infarction, 47% smoked at onset compared with 
30% at second screening of period I. The corresponding figures for CABG patients were 9% and 
7%, respectively, and for patients who had undergone PTCA, 30% and 33%, respectively. The 
proportion of smokers in the whole group fell significantly from 36 % at first screening to 26% at 
the second screening and had further decreased to 18% at the evaluation in period II (Paper I and 
II) 
Use of Medication 
The proportion of patients receiving pharmacological treatment for hyperlipidemia had doubled at 
the second screening as compared with the first screening in period I (Paper I), which further 
increased more than twofold, to 57% during period II after presentation of the 4S-study (Paper II). 
During the same period, in patients using lipid-lowering drugs, the use of statins increased from 
slightly more than half to 94%. The proportion of patients being treated with anti hypertensive 
drugs was 71% and 76% (including treatment for other reasons than hypertension) at first and 
second screening, respectively (period I). During the same period, the proportion of patients who 
were on treatment for diabetes was slightly above ten percent (Paper I). 
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The impact of the secondary prevention programme (Paper I) 
Only 39 patients (13%) approached the nurse involved in the secondary prevention program. The 
principal reason for visiting the nurse was hyperlipidemia. In the group that underwent nursing 
intervention, there were favourable results with regard to blood lipids but not, however, for the 
remaining risk factors such as fasting blood glucose, blood pressure or smoking (see Table V, 
Paper I, for further details). 
Validation of smoking cessation with bio-chemical markers (Paper III) 
Of former smokers, 260 (84 %) were validated by biochemical markers for smoking, i.e. cotinine 
in plasma or carbon monoxide in expired air. Cotinine in plasma was analysed in 206 patients. 
Fifty subjects had more than 14ng ml"1 cotinine in plasma that was the cut-off point for smoking 
but 37 of these used some kind of nicotine replacement therapy or moist snuff. Thirteen patients 
had concentrations of cotinine in plasma above 14ng ml"1 (median 53.9, range 14.3 - 313) without 
the intake of any nicotine replacement therapy or snuff. Carbon monoxide in expired air was 
measured in 247 patients. Six subjects had carbon monoxide that exceeded the cut-off point for 
smoking (i.e. CO >10 ppm). Both markers were elevated in two subjects. Thus, 17 (19-2) patients 
contradicted their self-report of having stopped smoking. This implies that 6.5 percent ( 17/260) or 
every fifteenth ex-smoker misrepresented their smoking habits. 
Smoking habits and predictors for continued smoking (Paper IV) 
Smoking habits 
Data regarding smoking habits were available from 1320 patients admitted to the hospital for acute 
coronary syndromes, 557 (42%) of whom were ex-smokers, 329 (25%) non-smokers and 434 
(33%) were current smokers. At follow-up, three months after discharge, smoking habits were 
available for 85% (n=348) of smokers who survived. At that point, 51% reported that they were 
still smoking, 49% that they had quit smoking. 
Health beliefs and motivation to quit smoking 
Only 54% (189/348) of the smokers available for follow-up had responded to the questionnaire 
they had received during hospitalisation regarding motivation to quit smoking and health beliefs. 
Of those who continued to smoke (non-quitters), 94% had thought of quitting and 72% had tried to 
quit. The majority had a strong (quite a lot or very much) belief that smoking had affected their 
health or was related to their heart problem. Sixty-seven percent believed that it was possible to 
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avoid heart problems in the future by quitting. There were no significant differences between non-
quitters and quitters in the variables measuring motivation and health beliefs. 
Predictors for continued smoking 
Factors that were independently associated with smoking status at 3 months follow-up were; non-
participation in the cardiac rehabilitation programme, treatment with sedatives or anti-depressants 
at the time of admission, a known cardiac event prior to hospital admission, a history of either 
cerebral vascular disease and/or smoking-related pulmonary disease and a higher average cigarette 
consumption prior to the event. Presence of any of these factors was associated with a higher risk 
of continued smoking. 
Patients' experiences of secondary prevention (Paper V) 
Two themes were identified in the analysis. The themes were described as; 'the impact of 
medication ' and 'the impact of health care professionals 
The theme 'the impact of medication ' was further described in three sub-themes: dealing with 
symptoms related to the medication, feeling intruded upon and feeling safe, reflecting different 
dimensions of being medicated after the heart attack. Patients had to deal with manifestations of 
different symptoms, such as bloated stomach, tiredness and dizziness, which occurred after the 
heart attack. These symptoms, described as a consequence of being medicated rather than as a 
result of having had a heart attack, forced the patients to return to the hospital and also to be 
readmitted. Information about the specific side effects led to patient expectations of their 
manifestations. Patients questioned whether the medication was good for them and how they could 
obtain information regarding this. By taking medicines daily and the information that the treatment 
would last a lifetime, patients were continuously reminded of the fact that they were heart attack 
victims. On the other hand, the patients' narratives indicated feelings of security and confidence 
and a belief that taking medicines regularly reduced the risk of a new heart attack. 
The theme 'impact of health care professionals ' was further described in three sub-themes 
reflecting different aspects connected with communication with health care professionals during 
the process of care; 'Receiving conflicting information 'wanting reassurance from the physician ' 
and 'experiencing the period after discharge as uncertain and precarious Communication with 
different health professionals led to feelings of uncertainty and worries about the condition of the 
disease. The patients wanted a dialog with the physician about the implications of the heart attack 
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and about what the different treatments meant. A feeling of uncertainty about the future and to 
what extent they could resume normal activities was described. Being examined by a physician 
after discharge was important as a mean of reducing feelings of uncertainty. 
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DISCUSSION 
Discussion of the use of methods 
Blood pressure measurement 
In this study, conventional clinic measurement of blood pressure was used to define the level 
of blood pressure, mostly by one reading, but if values deviated from previous readings mean 
value of two or three measurements was recorded. Blood pressure measured at the clinic may 
be unrepresentative of the patients' average blood pressure as it is usually higher than 
readings taken at home or by ambulatory monitoring (Mancia et al. 2002). The literature 
about blood pressure measurements show that ambulatory blood pressure is lower than 
clinical blood pressure by about 5-15 mmHg as pointed out by Muldoon (Muldoon et al. 
2003). However, home readings or ambulatory monitoring do not seem to provide a useful 
alternative to the conventional clinic measurement, which, according to Stergiou, was due to 
disagreement between methods to diagnose hypertension (Stergiou et al. 2000). On the other 
hand, there can be a prognostic value of ambulatory blood pressure recordings in patients with 
treated hypertension (Clement et al. 2003). As blood pressure levels tend to decline with 
repeated readings obtained at the clinic (Stergiou et al. 2000), measurements from multiple 
occasions are essential. Clinical guidelines about blood pressure recommends that at least two 
measurements should be made and the average recorded (Chobanian et al. 2003). 
Validation of smoking status 
To measure the presence of any substance it is necessary to use a method that is specific for 
that substance. To measure the presence, if any, of nicotine a method that is specific for 
nicotine, i.e. cotinine in plasma was used. Measurements based on cotinine are regarded as the 
most reliable method to validate smoking status, although it is not possible to differentiate 
between those who are using nicotine replacement therapy or snuff (Jarvis et al. 1987; Gilbert 
1993). Carbon monoxide is not specific for tobacco smoke; it is also a component of air 
pollution caused by exhaust fiimes from vehicles. In this study, we measured CO in expired 
air as a complement. This kind of test has been evaluated in several studies and found to be an 
acceptable validation method of smoking status (Gilbert 1993) and is to be preferred if the 
subjects are using any kind of nicotine replacement therapy. Apart from asking the patients 
about their smoking habits, there is at the present time, to our knowledge, no other way of 
detecting smoking than by biochemical markers. 
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Questionnaire about motivation and health beliefs 
The questionnaire, containing five questions aimed at measuring motivation and beliefs, used 
in this study was constructed before the study in an attempt to gain knowledge about patients' 
motivation to quit smoking and whether the patients' beliefs regarding smoking do matter. 
Though the stage of change model, where smokers are assigned to one of five stages of 
motivation as previously described, has been widely adopted in measuring motivation to stop 
smoking, no evidence exists that this method predicts smoking cessation better than other 
method assessing a smokers' motivation to stop smoking. Most smokers admitted for an acute 
coronary syndrome may pass through the previous stages to the stage of action (trying to stop) 
immediately, which is why it may not be appropriate to ask if they are planning to stop in the 
near future. According to West (West 2004), motivation to stop smoking can also be 
assessed by means of simple questions, the patients' interest and intention to quit or by asking 
the smoker to rate a degree of desire to stop on a scale from "not at all" to "very much". 
Unfortunately there were only 54% of the patients that responded to our questionnaire, which 
was why it was difficult to draw any conclusions regarding its usefulness. 
The interview in the qualitative study and interpretation of the data 
In the in-depth interview, patients were asked to reflect upon the heart attack and the time 
after discharge. Efforts were made to let the patients direct the narrative and to encourage, by 
nods and sometimes clarifying questions, a rich and profuse narration of their experiences in 
relation to secondary prevention. Due to the fact that the interviewer had an extensive clinical 
knowledge about the study field, efforts to allow the patient to narrate fully were made 
without the interviewers own point of view being apparent. There can be a problem in 
qualitative research in that a researcher already has some knowledge about the phenomenon 
being studied, but according to van Manen (van Manen 1990) we can not simply try to ignore 
what we already know, instead we can try to make explicit our understandings and beliefs so 
that we are conscious of them. 
Validity and reliability are criteria in both quantitative and qualitative studies. Validity 
ensures that the researcher measures what is intended to be measured and reliability ensures 
the quality of the method used to collect data. According to Guba (Guba 1985), the term 
"trustworthiness" is more useful than "validity" in relation to qualitative work. 
Trustworthiness involves credibility, transferability and conformability, all of which were 
taken into account in this study. Credibility was ensured in that patients who participated in 
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the interviews were identified and described accurately. Further, the findings are transferable, 
relevant and applicable to other contexts. A clear description of the analytical process was 
achieved: data were linked to their sources so the reader could establish that the interpretation 
was derived from the original sources and thus credible. Other researchers can also be helpful 
to validate the interpretation of the data; in this case, the supervisor helped to do this. 
Discussion of the results 
Evaluation of risk factor modification management 
Lipid levels and blood pressure 
The occurrence of traditional risk factors in out-patients with established coronary heart 
disease was described in 1993 and 1996. We found that the majority of patients had at least 
one modifiable risk factor with only minor changes over time. Other contemporary studies 
(Qureshi et al. 2001) also shown a high prevalence of various risk factors in this group of 
patients. 
Over time there were improvements in serum lipid levels due to an increased knowledge from 
secondary prevention trials about the benefits of lipid-lowering treatment (The 4S-study 
Group, 1994; Sacks et al. 1996; LIPID Study Group,1998; Heart Protection Study 
Collaborative Group, 2002; Cannon et al. 2004), which is a trend that can be seen in other 
studies as well (Vale et al. 2002). 
The treatment targets for plasma lipids have successively decreased. In general the goal for 
total cholesterol should be below 5 mmol/1, and LDL below 3 mmol/1, but for patients with 
clinically established coronary heart disease and for patients with diabetes the treatment goals 
should be below 4.5 mmol/1 and 2.5 mmol/1 for total- and LDL-cholesterol, respectively 
according to the latest European guidelines (De Backer et al. 2003). 
More recent published studies from Europe (De Backer 2002) and Australia (Vale et al. 2002) 
report that there is still a high prevalence of modifiable risk factors among coronary patients. 
The Euroaspire II cohort study (De Backer 2002) provided a comprehensive view on the 
management of patients with established coronary heart disease during the period 1999-2000 
in fifteen European countries on patients with established coronary heart disease. This study 
demonstrated that one out of five patient smoked, about one third was diagnosed as obese, 
35 
almost half of the patients being overweight, more than half had raised blood pressure and 
elevated serum total cholesterol at a median of 1.4 years of follow up. In overweight or obese 
patients, the control of raised blood pressure was significantly worse, with more than half of 
those using blood pressure-lowering medication having a blood pressure over the treatment 
target. The same result was obtained for the control of total cholesterol with 52% having more 
than or equal to > 5 mmol/1 (De Bacquer et al. 2004). 
The secondary prevention trial from Australia (Vale et al. 2002) also conducted during 1999-
2000, showed that only about half of the patients reached the target value for total cholesterol 
of less than 4.5 mmol/1. With an even lower limit of less than 4.0 mmol, almost three quarters 
of patients did not achieve that target. 
How many patients not achieving targets for blood pressure control as well as for lipid values, 
is a matter of at which level the targets is set. The most recent European guidelines on 
cardiovascular disease prevention in clinical practice recommends a goal for blood pressure of 
less than 140/90 mmHg in all high risk subjects, in patients with diabetes the goals are even 
lower (De Backer et al. 2003). When we applied the recent recommendations for therapeutic 
target for blood pressure of less than 140/90 mmHg on our data from 1993, we found that 
50% had a blood pressure above this level (unpublished data). 
Similarly, data from the above-mentioned studies from Australia and Europe revealed that 
about 40% to 50% of the patients in secondary prevention do not achieve their target goals for 
blood pressure control (Vale et al. 2002; Boersma et al. 2003). The Euroaspire II study 
(Boersma et al. 2003) also revealed that 86% of the patients were taking blood pressure-
lowering medication (not necessarily taken as an antihypertensive treatment), but only half of 
them achieved recommended goals for blood pressure control. A very high prevalence of 
elevated blood pressure was observed in this study among patients with other cardiac risk 
factors such as diabetes, high cholesterol and obesity, suggesting that the concept of total risk 
management is insufficiently implemented in clinical practice. The presence of other 
cardiovascular risk factors and the under use of combination medical therapy may contribute 
to the poor blood pressure control according to Amar and colleagues (Amar et al. 2003), as 
well as under use of other blood pressure lowering therapies, including diet (Boersma et al. 
2003). 
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It has also been observed that in treated hypertensive patients, systolic blood pressure control 
was less frequent than diastolic blood pressure control (Mancia et al. 2002). This may be 
related to a less effectiveness of current hypertensive drugs in lowering systolic blood 
pressure than diastolic blood pressure as suggested by Mancia (2002). Further, physicians 
may titrate antihypertensive treatment on the results of diastolic blood pressure and terminate 
further therapeutic efforts once diastolic blood pressure values are lower than 90 mmHg 
(Mancia et al. 2002). The same authors suggested that systolic blood pressure control might 
require more aggressive drug treatment than diastolic blood pressure control (Mancia et al. 
2002). Apart from physician-related and drug-related factors, patients' non adherence to 
hypertensive therapy has also been discussed to explain the problem of uncontrolled 
hypertension in clinical practice (Lindholm 2002). Other factors such as a lack of 
consciousness among patients regarding their hypertensive status and miscommunication 
between doctors and patients have been suggested to, at least partly explain, why so many 
patients have high blood pressure in secondary prevention. For example, in the Euroaspire II 
study (Boersma et al. 2003), about one third of the patients who believed that they had never 
been diagnosed with hypertension, actually had a blood pressure above 140/90 mmHg and 
thus were unaware of their hypertensive status. In this study, a number of patients with 
elevated blood pressure remembered their latest blood pressure as 'normal' indicating that 
health care professionals erroneously had judged the measured blood pressure as normal. 
Accordingly, patients who are unaware of their hypertensive status and patients who think 
that their blood pressure is 'normal' despite an elevated measurement, might be less likely to 
use a specific diet or to comply to the recommended treatment. 
Thus, it appears as though even today a very high proportion of patients with established 
coronary heart disease have elevated lipid levels and blood pressure amenable to treatment. 
Smoking 
The findings in this study showed that a high proportion of smokers continue to smoke after 
having suffered an acute coronary syndrome. The strongest predictor for continued smoking 
was non-participation in the heart rehabilitation programme. The programme (i.e. five group 
information lectures followed by physical training twice a week) is offered to every heart 
patient during hospitalisation. Approximately 80% of all patients participate in the group 
lectures of which 70% continue with the physical training. (Personal communication with the 
heart rehabilitation clinic at Sahlgrenska University Hospital. Unpublished data). In this study 
37 
only 56% of quitters and 34% of non-quitters participated in the group lectures (Table 3, 
Paper IV). Unfortunately, there was no information on how many continued with the 
physical training. However, the low participation rate by the smokers as a group may indicate 
that those who did not participate may be a very selected group of less motivated patients, 
which might partly explain the association between continued smoking and non-participation 
in the rehabilitation programme. It is most likely that the information given in the programme 
did help to support smoking cessation. The finding in this study is supported by other studies, 
which showed that non-participation in cardiac rehabilitation was also a predictor of current 
smoking (Tzou et al. 2004). 
In general, smokers state health reasons as a motive to quit smoking. Why patients with 
previously known cardiovascular health problems continued to smoke also after yet another 
event, is presumably associated with the selection of patients with less motivation to quit 
smoking. Those who are motivated may give up smoking the first time they suffer a serious 
health problem. 
Some patients do not admit their smoking status to health professionals. Do they fear to be 
blamed by the health professionals to have caused their health problem? Do health 
professionals unconsciously blame the patients for having caused their health problem 
themselves? However, smokers hospitalized with a diagnosis of coronary heart disease are 
being informed of smoking as a strong contributing factor for the cause of their disease and 
the benefits of quitting smoking for their prognosis. Their knowledge of the harmful effects of 
smoking and a strong pressure from health professionals to quit smoking may also have 
encouraged them to under-report their smoking status. If they then not succeed in doing this 
and continue smoking, they may feel shame and guilt. An under-report of smoking status has 
also been seen among patients with other health problems such as diabetes (Ellard et al. 1996; 
Smith et al. 1998), hypertension (Agewall et al. 2002), respiratory disease (Lewis et al. 2003) 
and cancer (Sandhu et al. 2004). Expectations from health care professionals for patients to 
quit smoking may be a reason why they would underreport their smoking status. Patients may 
therefore wish to give a more socially desirable response concerning their smoking habits as 
they have been hospitalised for an illness that may be regarded as smoking-related. 
To summarize the discussion about smoking and validation of patients smoking status, 
patients who did not succeed to quit smoking do not always admit this, but testing their 
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reliability by biochemical markers would not produce better results. Routine use of such 
testing is not recommended due to the ethical dilemma involved when finding high levels of 
biochemical markers in patients who do not admit smoking. Accepting information about 
smoking habits offered by the patients in secondary prevention provides a good starting point 
for health professional to motivate and support their patients towards a healthy change. 
Patients' experiences after a first myocardial infarction in relation to secondary 
prevention 
Impact of medication 
Findings in this study revealed that patients after a first myocardial infarction had to deal with 
symptoms that were more or less related to the medication (Paper V). The patients, who in 
many cases were not used to a regular use of medication before the infarction, also had mixed 
feelings about the medication they were ingesting. These findings indicate that the medication 
had a great impact on patients' life after a first myocardial infarction. Therefore, the most 
important information to give to the patients in secondary prevention is to explain that the 
medication is protecting the heart and the vascular system against complications in the future. 
According to others, knowing the beneficial effects of the medication, also knowing side 
effects, if any, in the long term seems to be important to patients (Bailey et al. 1997; Lisper et 
al. 1997). However, the patients in this study described that there were few opportunities to 
ask about the medication at discharge, due to an often stressful situation at that time. Although 
information about medication later in the rehabilitation period was given to the patient's it 
does not seem to be sufficient. In other studies dealing with hypertensive patients, little effort 
was made on discussing the effect and goal of therapy, which led to an incomplete 
understanding among the patients of the functional nature of their antihypertensive medication 
(Kjellgren et al. 1998). Benson and Britten (Benson et al. 2002) found that patients' ideas 
about drugs, may not be related to the drugs' pharmacology which is why it becomes 
important to personalise information about the medication. As many patients are active in 
searching information from other sources other than from health professionals about their 
medicines, they also need to discuss this information so misconceptions can be avoided. This 
is of special importance in the prospect of a life-long treatment such as in patients with 
coronary heart disease. Other studies, mostly qualitative, in this field have demonstrated that 
patents with various chronic conditions have several tensions and ambivalence in relation to 
drug use (Britten 1994; Townsend et al. 2003), and furthermore, concerns over the medication 
and the effect it may have on their body in the long term (Jaarsma et al. 1995; Roebuck et al. 
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2001). Despite these concerns, the medication was seen as a security and a protection for 
future complications by the patients. From the perspective of the patients the benefits of the 
medication, the eventual side effects as well as their concerns and beliefs about the 
medication, have to be taken into account when educating the patients after a heart attack. 
Impact of health professionals 
This study revealed that how health professionals communicate with the patients had a great 
impact on patients' life after a heart attack. Also shown was that patients had feelings of 
uncertainty, a finding also described in other studies (Jackson et al. 2000; Jensen et al. 2003). 
The uncertainty patients described in this study were often related to symptoms they observed 
and their physical function after the heart attack. The communication with different health 
professionals, who in some cases gave information that was difficult for the patients to 
interpret, or sometimes also conflicting, may also have contributed to the uncertainty. Other 
studies have reported an unmet need for reliable information among women (Jackson et al. 
2000). Following a heart attack, people try to regain control over their life situation and also 
try to become independent (Johnson 1991; Sutherland et al. 2000). They also try to structure 
their environment differently to facilitate lifestyle changes, a process where they integrate 
their beliefs and attitudes into changed behaviour (Frenn et al. 1989). As patients did not seem 
to trust their own observations or even when to resume their normal activities, reassurance by 
health professionals to reduce the uncertainty and to help patients to regain control over their 
situation and become independent, is of importance. Patients' perception of their illness 
influences their functioning and has been shown to play an important part in determining 
whether patients resume their work after a myocardial infarction or CABG (Petrie et al. 1996; 
Mittag et al. 2001). It is, therefore, important to take this into account when communicating 
with patients. Providing information that is relevant and also possible for the patients to 
understand was underscored in this study. 
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Limitations and considerations 
The two first studies (Paper I, II) were conducted in an early era of secondary prevention where 
the routines in the clinic not were yet developed, so there were many problems in implementing 
secondary prevention in daily practice. The problems in our study were apart from inadequate risk 
factor control also incomplete risk factor recording in patients' medical journal. There are other 
difficulties to overcome when implementing evidence and clinical guidelines into routine daily 
practice, of which some have been suggested to relate to practitioners in hospital or primary care, 
others to patients and their relatives (Shepherd 1999). 
There was no active referral to the nurse who was involved in the secondary prevention 
programme (I). It was left instead to the responsible physician to refer the patients. Only a small 
number of the patients were referred to the nurse, which hampered an evaluation of the 
programme. More effort should have been made to actively recruit all eligible patients to the 
secondary programme in order to make it possible for evaluation. To evaluate the impact of the 
programme on the pattern of risk indicators even more efficiently, we could have involved a 
control group with standard care and one secondary preventive nurse care group. This type of 
study design with a control group would have improved the possibilities to evaluate the 
programme. 
A limitation of validation of patients smoking status with biochemical marker may have been 
the fact that patients knew of the test beforehand, which may have influenced how they were 
going to answer the question about their smoking status. Those who had thought of not 
claiming that they smoked had maybe changed their mind due to this. In that case there is an 
under estimation of smokers who do not admit smoking. Among the patients who fulfilled 
inclusion criteria there was quite a large amount of withdrawals of patients who failed to 
come, and patients who were unwilling to give samples to prove their ex-smoking status. Of 
the former smokers who came to the nurse, about 20% (60/286) did not want to give blood 
samples for measurements of cotinine, of whom 26 did not want to give breath CO either. It is 
unknown why they were unwilling to be tested but one can suspect that the decision was 
associated with their smoking status. If all these 26 patients were telling the truth about their 
ex-smoking status it only changed the proportion of smoking deceivers marginally to 5.9%. 
On the other hand, if more than one of the patients had been classified as a smoker by the 
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biochemical marker, the proportion of those who contradicted their self-report would increase. 
Thus, one can surmise that the estimated proportion is reasonable accurate. 
The evaluation of the secondary prevention programme only encompassed patients below 70 years 
of age. This age limitation was made due to practical reasons in the clinic. Further, we do not know 
anything about patients who were unwilling to participate. This is a problem shared by all clinical 
studies. 
In this study we did not associate the various risk indicators and their management with the clinical 
events during follow up. We considered that the study population was too small to estimate such 
an association in a meaningful way. 
We did not address psychosocial factors such as depression, social support and work 
characteristics or physical inactivity, which also have been associated with an adverse prognosis in 
patients with various manifestations of coronary heart disease (Wenger et al. 1995; Hemingway et 
al. 1999; Frasure-Smith et al. 2003). We understand the value of these risk factors but 
measurements of these variables may be more difficult to obtain, and may also be more difficult to 
redress. 
Aims, main results and conclusions 
The aims of this study, as described in the beginning of this thesis, are written in italic font 
style, together with main results and conclusions. 
• What is the occurrence of traditional risk indicators associated with recurrence in 
outpatients with established coronary heart disease? 
A high proportion of traditional risk indicators associated with recurrence were found. Among 
those who had developed myocardial infarction and among those in whom CABG or PTCA were 
undertaken the proportion appeared to be similar except from smoking habits, which was lower 
after by-pass operation. Nonetheless, a high proportion of patients with established coronary heart 
disease have risk factors amenable to treatment. 
• Does increased knowledge about the beneficial value of lipid lowering treatment influence 
secondary prevention in coronary artery disease? 
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Increased knowledge about the benefits of lipid lowering levels led to an increased use of 
lipid lowering drugs and improved lipid levels, and thereby influenced secondary prevention. 
• What is the reliability of self-report with respect to smoking cessation? 
Some contradictions (< 10 % of cases) were found in former smokers between self-report of 
smoking cessation and biochemical markers for smoking. However, in the vast majority of 
former smokers, self-reported smoking cessation corresponded with the bio-chemical 
markers. 
• What predicts continued smoking in patients with acute coronary syndromes? 
Predictive factors for continued smoking were; whether the patients did not participate in the heart 
rehabilitation programme, whether they used sedatives or antidepressants or whether they had a 
history of cerebral vascular disease, a cardiac event or smoking-related pulmonary disease. If 
patients had a high level of cigarette consumption also predicted a continuation in smoking. These 
findings may guide the identification of patients at high risk for continued smoking. 
• What are the experiences of secondary prevention from the patients 'perspective? 
Patients interpreted bodily symptoms as a consequence of being medicated rather than as a result 
of the heart attack. Regarding the medication, there were indications that patients had feelings of 
being intruded upon, but also to positive feelings of security and confidence. Communication with 
different health professionals gave the patients an ambiguous perception of the disease and its 
treatment. From the patients perspective there was a need of being reassured of the physical 
function by the physician. 
Implications 
The management of risk factor modification in patients with established coronary heart 
disease have to be improved. Information from further clinical trials will influence the future 
risk factor modification. 
In the vast majority of patients with established coronary heart disease, self-report about 
smoking cessation is reliable. Routine use of testing the reliability of smoking cessation by 
biochemical markers is not recommended due to the ethical dilemma involved when finding 
high levels of these markers who do not admit to smoking. 
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It is possible to identify factors associated with an increased risk of continuation in smoking. 
Patients who suffer from any of these risk indicators might deserve specific treatment. 
From the patients' perspective, the benefits of the medication, the eventual side effects as well 
as patients' concerns and beliefs about the medication have to be taken into account when 
educating the patients after a heart attack. 
Clinical guidelines on how to improve information, education and counselling in secondary 
prevention have to be developed. 
Future aspects 
How should we improve smoking cessation rates? 
In helping patients to stop smoking, it is important to consider his or her degree of 
dependence on cigarettes as well as motivation to stop smoking as these two factors often are 
related to each other (Russell 1977). These factors can be assessed by simple questions. The 
point of why we should assess motivation is to identify those who are ready to make a quit 
attempt. It has been suggested that the main value of measuring dependency is the choice of 
pharmacotherapy (West 2004). Theoretically the level of physical dependence on nicotine 
determines the dosage of nicotine replacement therapy, but results from studies to prove this 
have been conflicting (Herrera et al. 1995; Garvey et al. 2000). According to West (2004), 
when an individual is motivated and has made a decision to quit, the success of that quit 
attempt may be determined more by the degree of dependence than to the level of motivation. 
The most effective interventions combine behaviour support with drug treatment as 
highlighted by Coleman (Coleman 2004). Research has shown that smoking cessation advice 
and support from health professionals and pharmacotherapy (Nicotine replacement therapy or 
Buproprion), can enhance the chances of success (Cochrane Reviews: Silagy et al. 2004; Rice 
et al. 2004). Starting already during hospitalization with repeated brief and supportive advice 
on smoking cessation should therefore be given and reinforced by the doctors and other health 
professionals engaged in the aftercare of the patients. Behavioural support to prevent relapse 
along with follow up should also be considered (Rigotti et al. 2003). 
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Buprion (Zyban), which is a non-nicotine based treatment for use in smoking cessation 
treatment has been shown to be a valuable medication for smoking cessation in smokers with 
cardiovascular health problems (Tonstad et al. 2003). Using this drug, more than twice as 
many smokers had quit smoking at one year compared with placebo. 
Use of nicotine replacement therapy is also an effective component of smoking cessation 
strategies and should be recommended routinely to heavier smokers (defined as those 
smoking more than 10 cigarettes daily), as a smoking cessation therapy according to a review 
conducted by the Cochrane Library. (Silagy et al 2004). I believe, however, that health 
professionals should recommend this therapy to all smokers. As no smoking cessation devices 
are a panacea, the patients' have to make strong efforts to quit smoking and to sustain a 
smoke-free status. Patients' have a tendency to overestimate their ability to quit smoking and 
underestimate the difficulties. 
As cigarette dependency is a chronic relapsing condition (Jarvis 2004), patients that have 
made a quit attempt may struggle over years to achieve long-term abstinence. They should 
therefore be asked about their current smoking status at any encounter with all health 
professionals and, if needed, referred to a nurse dedicated to secondary prevention for further 
help. The challenge for health professionals will be to incorporate smoking cessation efforts 
as part of standard practice, so that all patients are given an opportunity to be asked about 
their tobacco use and to be given advice and/or counselling to quit along with reinforcement 
and follow-up, as concluded by Rice (Rice et al. 2004). 
Strategies that may help patients to stop smoking can be summarized into the following A's as 
underlined in the European guidelines on cardiovascular disease prevention (De Backer et al. 
2003) outlined in the box below. 
A - ask: systematically identify all smokers at every opportunity 
A - assess: determine the patient's degree of addiction and her/his 
readiness to cease smoking 
A - advice: urge strongly all smokers to quit 
A - assist: agree on a smoking cessation strategy including 
behavioural counseling, nicotine replacement therapy 
and/or pharmacological intervention 
A - arrange a schedule of follow up visits 
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How can blood pressure control in patients be improved in secondary prevention? 
Lifestyle modifications such as weight loss, sodium reduction, increased physical activity, and 
limited alcohol intake can lower blood pressure directly or indirectly (Appel et al. 2003), and 
should be recommended to all hypertensive persons according to Appel (Appel 2003). In a 
meta-analysis of randomized controlled trials done by Neter and co-workers (2003), it was 
estimated that a weight reduction by means of energy restriction and increased physical 
activity or both reduced the blood pressure by about 1 mmHg per kilogram (Neter et al. 
2003). An overall healthy dietary pattern termed the dietary approach to stop hypertension 
(DASH), a diet that emphasizes fruits, vegetables, and low-fat dairy products can also be 
effective in lowering blood pressure (Harsha et al. 1999; Conlin et al. 2000). This diet in 
combination with sodium reduction may have even better effects (Sacks et al. 2001). 
Other aspects 
Lipid lowering therapy will, in the future, be even more intensified to further reduce the risk 
for recurrent events (Cannon et al. 2004). There is also a potential to further improve the 
overall pharmacological treatment as there has been reported an under use of drugs in 
secondary prevention (Mukherjee et al. 2004). 
Taking this into consideration that patients have to be reassured of their physical function, an 
exercise test after the infarction conducted by the physician may be useful for this 
confirmation and for prognostic information (Karlsson 2001). In addition, to motivate the 
patients to participate in the cardiac rehabilitation programme is also important. In the future 
planning of the patients' care after discharge from hospital for a first myocardial infarction, it 
is important for the patients to receive at least one follow-up visit to a cardiologist or other 
physician with time to discuss all questions that the patients may have. This may also apply to 
patients who have undergone revascularization therapies, as the length of hospital stay for 
these patients, as well as for patients with acute myocardial infarction, has declined. 
Concluding remarks 
To be maximally effective, as suggested by Sebregts, risk management should focus on a 
selection of patients most likely to benefit from a particular programme, or even better, 
patients should be referred to the treatment, which is most appropriate for their special needs 
(Sebregts et al. 2000). General guide lines for cardiac rehabilitation and secondary prevention 
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emphasizes individual sub-goals based on patients' needs (De Backer el al. 2003). To be able 
to do this, it is important that health professionals listen to the patients and identify their 
needs. It seems as if the present communication is non concordant with the patients' needs. 
The clinical challenge for health professionals is to improve and develop the present guide 
lines to be suitable for daily practical work, particularly concerning communication with the 
patients regarding information, education and counselling. 
47 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Problem associerade med modifiering av riskfaktorer i sekundärprevention av 
kranskärlssjukdom 
Avhandlingen handlar om att förändra riskfaktorer hos patienter som har vårdats på sjukhus 
på grund av en kranskärlssjukdom, samt om patienternas upplevelser efter en första 
hjärtinfarkt. 
Patienter vilka sjukhusvårdats under 1993 och 1995-1996 för en konstaterad kranskärlssjukdom 
identifierades ett år efter hjärthändelsen och förekomsten av riskfaktorer associerade med 
återinsjuknande utvärderades. Utvärderingen skedde efter införandet av ett sekundärpreventivt 
program på hjärtkliniken. Patienterna erbjöds besök till sjuksköterska på hjärtmottagningen för 
utvärdering av sina riskfaktorer och om dessa förbättrades över tid. Vid de uppföljande besöken 
validerades även patienternas uppgift om rökstopp med kemiska markörer for rökning, kotinin i 
plasma och kolmonoxid i utandningsluften. Vid den första utvärderingen hade 70 % av alla 
patienter en eller flera av följande riskfaktorer; total kolesterol >6,5 mmol/1 (30 %), triglycerider 
>3,0 mmol/1 (19%), fasteblodsocker >6,7 mmol/1 (29 %), systoliskt blodtryck >160 mmHg (9 
%), diastoliskt blodtryck >90 mmHg (8 %) eller rökning (36 %), jämfört med 67 % vid 
uppföljningen 1 till 2 år senare. Således hade det sekundärpreventiva programmet begränsad 
effekt på det totala riskfaktormönstret, men över tid observerades en markant sänkning av 
blodfetter parallellt med en trefaldig ökning av användningen av lipidsänkande läkemedel. Även 
andelen patienter som rökte sänktes märkbart. Vi fann ingen förändring i pat ienternas kroppsvikt 
under de båda utvärderingsperioderna. 
Rökvanor hos 1320 patienter registrerades vid vårdtillfället under en 4-års period och faktorer 
som kan förutsäga rökstopp identifierades. Vi fann att 33 % uppgav att de rökte vid 
vårdtillfället, vid uppföljningen 3 månader senare uppgav hälften av dem att de hade slutat 
röka. Sex faktorer var associerade till rökstatus vid uppföljningen, nämligen att inte ha 
deltagit i hj ärtrehabiliteringen, behandling med lugnande läkemedel eller läkemedel mot 
depression vid inläggningen på sjukhuset, om patienterna hade en tidigare känd hj ärthändelse, 
cerebrovascular sjukdom eller rökrelaterad lungsjukdom. Dessutom hade en hög cigarett 
förbrukning betydelse för om patienterna forsatte att röka. Vi fann att 17 (6,5 %) patienter 
som uppgav att de slutat röka hade förhöjda värden av kolmonoxid (n=6) och/eller kotinin 
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(n=13), utan alternativt intag av nikotinersättningsmedel. Egna uppgifter om rökstopp stämde 
dock i de flesta fall med den kemiska markören. 
Resultat från en intervjustudie visade att medicineringen och uppföljningen efter 
förstagångsinfarkt kunde upplevas förvirrande och motsägelsefull. Patienterna tolkade 
symptom som en konsekvens av att vara medicinerad och relaterade inga kroppsliga obehag 
till hjärtinfarkten. Medicineringen ledde till en känsla av intrång i det dagliga livet men 
upplevdes också som säkerhet och skydd mot en ny infarkt. Kommunikation med olika läkare 
och övrig vårdpersonal gav en oklar bild av sjukdomen och dess behandling. Tiden efter 
sjukhusvistelsen kändes osäker och vansklig. Patienterna verkade ha ett stort behov av att bli 
bekräftad i sin fysiska funktion av läkaren. 
Sammanfattningsvis kan vi konstatera att det finns svårigheter att förändra riskprofilen vid 
sekundärprevention efter konstaterad kranskärlssjukdom. Fastän en avsevärd förbättring i 
behandlingen av blodfetter har skett främst genom en ökad användning av blodfettssänkande 
läkemedel, kvarstår problem med förändring av andra riskfaktorer som övervikt och rökning. 
Med de ännu lägre behandlingsmålen för blodtryck och blodfetter som är aktuella idag finns 
det potential för förbättring även av dessa riskfaktorer. Vidare framkom att patienterna, vilka i 
många fall tidigare inte behövt regelbunden medicinering, upplevde medicinerna som ett 
intrång i livet. Alla kroppsliga obehag relaterades till medicinerna som trots allt accepterades 
eftersom de också gav ett visst skydd mot nytt insjuknande och för tidig död. Vårdpersonalens 
information och uppföljning var uppskattad men upplevdes som motsägelsefull och otydlig. 
Utgångspunkten i det sekundärpreventiva arbetet bör vara patienternas upplevelse av sitt 
tillstånd och den behandling som de får. 
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